Literature DB >> 11002258

Type 1-like immune response is found in children with respiratory syncytial virus infection regardless of clinical severity.

A H Brandenburg1, A Kleinjan, B van Het Land, H A Moll, H H Timmerman, R L de Swart, H J Neijens, W Fokkens, A D Osterhaus.   

Abstract

The immunological response of infants younger than six months to infection with respiratory syncytial virus (RSV) was studied in relation to clinical severity. IL-6 and IL-8 were found more frequently and at higher levels in the plasma samples of more severely ill patients and no significant differences were found in the levels of cytokines differentiating between Type 1 and Type 2 responses. Cellular infiltrates in nasopharyngeal washings consisted mainly of polymorphonuclear granulocytes and monocytes. Eosinophils, IgE positive cells and tryptase positive cells were found sporadically. Analyses of RSV stimulated T cell cultures established from peripheral blood mononuclear cells, for intracellular and secreted cytokines showed that, irrespective of clinical severity, the responses were dominated by the production of IFN-gamma, and that only low levels of IL-4 and IL-10 were detectable. Collectively these data do not indicate an association between clinical severity and a Type 2-like T cell response. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11002258

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  26 in total

1.  Airway IFN-γ production during RSV bronchiolitis is associated with eosinophilic inflammation.

Authors:  Chang Keun Kim; Zak Callaway; Young Yull Koh; Soo-Hee Kim; Takao Fujisawa
Journal:  Lung       Date:  2011-12-13       Impact factor: 2.584

2.  HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein.

Authors:  A H Brandenburg; L de Waal; H H Timmerman; P Hoogerhout; R L de Swart; A D Osterhaus
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 3.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

Review 4.  New insights for development of a safe and protective RSV vaccine.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Kari Ann Shirey; Gregory A Prince; Stefanie N Vogel
Journal:  Hum Vaccin       Date:  2010-06-01

Review 5.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

6.  Comparison of serum and cell-specific cytokines in humans.

Authors:  J Jason; L K Archibald; O C Nwanyanwu; M G Byrd; P N Kazembe; H Dobbie; W R Jarvis
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

Review 7.  Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.

Authors:  Charles J Russell; Eric A F Simões; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2018-01-11       Impact factor: 2.257

8.  Respiratory syncytial virus differentially activates murine myeloid and plasmacytoid dendritic cells.

Authors:  Ivette Boogaard; Marijke van Oosten; Leonie S van Rijt; Femke Muskens; Tjeerd G Kimman; Bart N Lambrecht; Anne-Marie Buisman
Journal:  Immunology       Date:  2007-04-30       Impact factor: 7.397

9.  A systemic neutrophil response precedes robust CD8(+) T-cell activation during natural respiratory syncytial virus infection in infants.

Authors:  Michaël V Lukens; Alma C van de Pol; Frank E J Coenjaerts; Nicolaas J G Jansen; Vera M Kamp; Jan L L Kimpen; John W A Rossen; Laurien H Ulfman; Carline E A Tacke; Marco C Viveen; Leo Koenderman; Tom F W Wolfs; Grada M van Bleek
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

10.  Plasma levels of inter-alpha inhibitor proteins in children with acute Dengue virus infection.

Authors:  Penelope Koraka; Yow-Pin Lim; Michael D Shin; Tatty E Setiati; Albert T A Mairuhu; Eric C M van Gorp; Augustinus Soemantri; Albert D M E Osterhaus; Byron E E Martina
Journal:  PLoS One       Date:  2010-04-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.